

REMARKS

Applicants have amended the Cross Reference to Related Applications in order to set forth the priority claim in the present application. Applicants submit herewith an Application Data Sheet, pursuant to 37 C.F.R. § 1.76(c)(1), which further recites the priority claim for the present application.

Applicants cancel claims 14-17, 24-26, 42, and 43 without prejudice to applicants' ability to file and obtain patent protection for claims directed to this cancelled subject matter in applications claiming priority to the present application under 35 U.S.C. § 120. Applicants amend claims 1-13, 18, 19, 21-23, 27, 33, and 34. Accordingly, claims 1-13, 18-23, and 27-41 are pending and under consideration.

Applicants amend claims 1, 4, 5, 8, 9, 12, 13, 19, and 23 to exclude previously prosecuted subject matter and to define the subject matter to be prosecuted in the present invention.

Applicants amend claims 1, 2, 3, 6, 7, 10, and 11 to replace the phrase "pharmaceutically acceptable derivative or prodrug" with the phrase "pharmaceutically acceptable salt". Claims 2, 3, 6, 7, 10, and 11 are further amended to recite "wherein the variables are as defined in claim 1".

Applicants have amended claim 18 to specifically list the compounds, which applicant considers part of the present invention, into the claims.

Claims 19 and 23 are amended to reflect proper dependency resulting from the amendment and cancellation of claims in the present application.

Claims 21 and 22 are amended to incorporate the specific therapeutic agents into the claim. Support for this amendment is found in the specification at page 53, line 13 through page 54, line 14.

Applicants have amended claim 27 to recite the step of the method. Said step was inadvertently omitted from the originally filed claim. Support for this amendment is found in the originally filed specification at pages 45 and 46.

Claims 33 and 34 are amended to replace the term "neurodegenerative disease" with the term "neurological disorder". This amendment is made to maintain consistency in the use of terms because, in claim 27, the term "neurological disorder" is recited.

Applicants respectfully request that the Examiner amend inventorship in the above-identified application pursuant to 37 C.F.R. §1.48(b). Although the correct inventors are named in the nonprovisional application as filed, there are fewer inventors

due to the amendment of claims during prosecution. Accordingly, applicants request that the name of Robert Mashal be deleted since his invention is no longer being claimed in the present nonprovisional application. Thus, the inventors of the present application are as follows:


Michael R. Hale
James W. Janetka
Francois Maltais
Jingrong Cao

Each of the above inventors is listed on the originally filed, and fully executed, Declaration and Power of Attorney, a copy of which is submitted herewith. Applicants authorize the Commissioner to charge payment of the fee required under 37 C.F.R. § 1.17(i), in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725.

None of these amendments add any new matter.

Applicants respectfully request that the Examiner consider the foregoing remarks and enter the indicated amendments prior to substantive examination of this application.

Respectfully submitted,



Andrea L. C. Robidoux (Reg. No. 47,902)
Agent for Applicants
C/O Vertex Pharmaceuticals Inc.
130 Waverly St.
Cambridge, MA 02139-4242
Tel: (617)444-6731
Fax: (617)444-6483